Trials / Unknown
UnknownNCT02255292
A Study: Pure CBD as Single-agent for Solid Tumor.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Increasing lines of evidence support an antitumourigenic effect of cannabinoids, including the cannabidiol (CBD) which does not posses the psychotropic effects of D9-tetrahydrocannabinol (THC). These include anti-proliferative and pro-apoptotic effects and they are known to interfere with several mechanisms in the tumorgenesis. Yet, evidence from clinical trials among cancer patients is needed. The aim of the current study is to evaluate the impact of CBD as single treatment among cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cannabidiol (CBD) | Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2 and aged 18 years old and more will be included in the current study |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2015-07-01
- Completion
- 2015-07-01
- First posted
- 2014-10-02
- Last updated
- 2014-10-02
Source: ClinicalTrials.gov record NCT02255292. Inclusion in this directory is not an endorsement.